Pluristem Therapeutics Inc. (NASDAQ:PSTI) Director Mark Germain sold 23,818 shares of the business’s stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $1.50, for a total value of $35,727.00. Following the transaction, the director now directly owns 559,817 shares of the company’s stock, valued at approximately $839,725.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Pluristem Therapeutics Inc. (PSTI) traded down $0.01 during trading on Thursday, hitting $1.47. The stock had a trading volume of 262,775 shares, compared to its average volume of 286,252. Pluristem Therapeutics Inc. has a 12 month low of $1.06 and a 12 month high of $2.12. The firm has a market cap of $166.25, a PE ratio of -4.59 and a beta of 0.21.
A number of institutional investors and hedge funds have recently modified their holdings of PSTI. Psagot Investment House Ltd. increased its holdings in Pluristem Therapeutics by 1,705.2% in the 3rd quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 122,347 shares in the last quarter. Jane Street Group LLC increased its holdings in Pluristem Therapeutics by 15.0% in the 3rd quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock worth $402,000 after purchasing an additional 34,742 shares in the last quarter. ARK Investment Management LLC increased its holdings in Pluristem Therapeutics by 363.5% in the 4th quarter. ARK Investment Management LLC now owns 290,922 shares of the biotechnology company’s stock worth $401,000 after purchasing an additional 228,149 shares in the last quarter. Finally, Meitav Dash Investments Ltd. acquired a new position in Pluristem Therapeutics in the 4th quarter worth about $138,000. 4.28% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have recently commented on the company. HC Wainwright set a $4.00 price target on Pluristem Therapeutics and gave the stock a “buy” rating in a report on Tuesday, January 16th. Zacks Investment Research raised Pluristem Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 22nd. Maxim Group set a $3.00 price target on Pluristem Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 21st. Finally, ValuEngine cut Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 20th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $3.44.
COPYRIGHT VIOLATION NOTICE: This news story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2018/03/15/pluristem-therapeutics-inc-psti-director-mark-germain-sells-23818-shares.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.